Challenges Of Particle Characterisation - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Challenges Of Particle Characterisation
Particle characteristics can affect pharmaceutical formulations and products in a number of ways, and a variety of techniques are available that enable particle monitoring and characterisation. The author discusses some of these techniques and describes how, in some cases, it can be beneficial to combine them in a complementary way whilst being aware of the different results they may provide.

Pharmaceutical Technology Europe
Volume 4, Issue 23

Linking laboratory with production

One key factor influencing the choice of technologies for particle size analysis is the desire to correlate lab results with production information gathered at various stages of the product cycle. However, each stage of product development and manufacture has a different focus, meaning that the analytical tools employed will vary.

Quality by Design (QbD) encourages the development team to identify and quantify correlations between key product variables and clinical performance, and to understand how these are controlled by the manufacturing process from the outset. At this stage, there is an urgent need for detailed knowledge and for instruments that provide a cost-effective route to its acquisition.

As a project moves through pilot plant development and into manufacture, the focus switches to tracking process dynamics and continuous monitoring, which means the measurement speed of the particle characterisation technology employed becomes critical. In particular, there is a need for systems that enable real-time process scoping, optimisation, monitoring and control. During production, effective analysis allows manufacturers to ensure that product quality targets are met consistently, thereby reducing reliance on pre-release quality control testing.

When it comes to quality control, the demands on particle characterisation systems change again. Here, one may not need to know the actual size of the particles. It may be enough to have a parameter that can be measured reproducibly and that correlates with a known performance characteristic of the drug. For example, if the particles are non-spherical, a Laser Light Scattering method may give a wildly inaccurate value for the true diameter of the crystals, yet give results that are consistent and, therefore, allow the setting of a specification.

Beneficial techniques

Because the tools employed will vary at each stage, maintaining a consistent specification during transitions from one technique to another can be complicated. As such, technologies that can be configured for both laboratory and process use, or those that neatly dovetail, are advantageous. Laser diffraction and automated image analysis are two such techniques.

Laser diffraction

Laser diffraction is a rapid measurement technique and an established on-line technology that enables real-time, on- or in-line particle size analysis for both wet and dry systems. Off-line laser diffraction can also be highly automated and robust after successful method development.

Laser diffraction can be used to develop particle size specifications in the early stages of a project, and then transferred into production via on-line technology. Many powders have particle size specifications and laser diffraction is often used as the sizing technique of choice for quality control in this regard. For some applications, however, size data alone will be insufficient to either fully characterise or define a material.

Imaging technology

As imaging technology has become more freely available, the influence of particle shape on performance has become increasingly well appreciated. Automated imaging overlays size data with statistically relevant information about shape, and can be useful for detailed development work in troubleshooting and root cause analysis. If two samples behave differently but are classified as identical by particle size analysis, morphology of the particles may hold the key.

Imaging is much faster than manual microscopy — data for tens of thousands of particles can be obtained in minutes — and, importantly, it produces more statistically relevant data. Parameters such as circularity, convexity and elongation can be measured and used to precisely define the shape distributions of a particle population. Each image can be scrutinised by eye if necessary, whereas size versus shape plots enable the identification of discreet particle populations like APIs and excipients with overlapping size distribution. The integration of spectroscopy into imaging systems adds a further powerful dimension to automated image analysis; Raman spectroscopy, for example, can characterise particles by size, shape and chemical composition.

Combining the benefits

Switching between image analysis and laser diffraction needs care — image analysis software is constrained to two dimensions — but it is entirely feasible and offers many advantages; for example, during method development for laser diffraction, imaging can identify the presence of any agglomerates. Imaging also adds a layer of detail that cannot be obtained through laser diffraction particle size analysis alone.

There are also times when manual microscopy proves a valuable addition to the particle characterisation armoury. In particular, microscopy plays a valuable role in identifying unknown and unwanted particles, i.e., foreign bodies, when linking X-ray diffraction to the scanning electron microscope to obtain data on chemical composition. In addition, it can be useful for assessing the mixing quality of two ingredients within a tablet. Similarly, infrared imaging microscopy can be used to analyse the distribution of organic molecules or particles in complex mixtures, such as tablet formulations and sediments. In both cases, these techniques can demonstrate whether there is good content uniformity and, by implication, whether there is good distribution of API across a production run.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here